INSIGHTS ON DRUG DEVELOPMENT

• An Unparalleled Window Into IBD Immune Response

  Discover how Organ-Chips provide an unparalleled view into the human immune response to IBD and allow researchers to accurately model the intricacies of immune cell recruitment.

• Efficacy Evaluation Of AAV-Delivered Liver-Specific Promoters

  Dr. Rui Sun, a Research Scientist at Bayer AG, discusses his work using Liver-Chips to assess the transduction efficiency and selectivity of liver-specific AAV promoters.

• AustinPX Site Tour

  Take a virtual tour of AustinPx to explore advanced facilities, including KinetiSol™ technology, and discover how we enable scalable, sustainable performance.

• How Process Intensification Supports A Sustainable Future

  Discover how process intensification is revolutionizing bioprocessing by boosting efficiency and reducing waste. Hear from experts on how these innovations are driving a more sustainable future.

• AI Based Screening And Selection Of Co-Formers For Co-Crystallization

  11/4/2025

  Explore how AI and quantum chemistry are accelerating co-crystal screening and solving solubility challenges in drug development, as well as key technical considerations for identifying optimal co-formers.

• API In Capsule Vs. The Lost Art Of Formulation Development

  11/5/2025

  API-in-capsule offers a fast path for early clinical data, but it can't eliminate the need for full formulation development. Weighing the potential for higher total development time and cost is critical.

• Reduce Costly Scale-Up Problems

  4/11/2024

  Scaling a new drug formulation from development to manufacturing often presents challenges, but there are ways to minimize deviations and streamline your transition.

• Fast And Scalable Fc Quantitation In Supernatants

  3/24/2025

  In biopharmaceutical development, the Fc PAIA Titer assay offers a fast, cost-effective, and automatable solution for high-throughput Fc quantification to enhance efficiency, support research, and accelerate production advancements.

• Automating High-Throughput Screens Using Patient-Derived Organoids

  3/17/2025

  Many oncology drugs fail in later development stages due to inadequate predictive models. Explore how 3D cell models, like patient-derived organoids, offer a promising solution in the drug development process.